-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
ViiV Healthcare recently reported the final data analysis of the IIb/III HPTN 083 study, which showed a 66% reduction in HIV incidence compared to Gilead Sciences' Truvada (Entouritham/Tinofovir) program, which includes a research-based long-acting cabottegravir pre-exposure prevention (PrEP).
midterm review, the blind period of the study stopped in May this year.
study showed that long-acting cabottegravir was 69 percent more likely to prevent HIV than Truvada.
findings will be presented at the International AIDS Congress (AIDS 2020) on July 8.
This advance has the potential to change AIDS prevention efforts, with long-acting cabotegravir given significantly less frequently and is expected to only be given six times a year," said Kimberly Smith, head of research and development at ViiV, which is controlled by GlaxoSmithKline.
HPTN 083 study, co-funded by the National Institutes of Health, was conducted in Argentina, Brazil, Peru, the United States, South Africa, Thailand and Vietnam.
participants receive cabottegravir every 8 weeks or oral Truvada every day for a maximum of three years.
the main efficacy endpoint of the trial is the recorded HIV infection event.
.
